MetaCap

BioCryst Pharmaceuticals (BCRX) vs Maze Therapeutics (MAZE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioCryst Pharmaceuticals (BCRX) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 3.6% versus a loss of 13.5%. BioCryst Pharmaceuticals is the larger company by market cap ($1.86 billion vs $1.72 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCRX+3.59%MAZE-13.49%
+64%+11%-43%
Nov 21, 20251 yearNov 20, 2026
BCRX-8.61%MAZE+96.68%
+228%+82%-64%
Jan 27, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCRX versus MAZE key metrics
MetricBCRXMAZE
Share price$7.22$31.37
Market cap$1.86B$1.72B
1-day change-1.37%-3.27%
YTD return-7.44%-24.28%
1-year return+3.59%-13.49%
5-year return-42.15%—
Forward P/E8.44—
EPS (TTM)$-1.28$-2.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$874.84M—
Revenue growth (YoY)+94.10%—
Net income (latest FY)$263.86M$-131.12M
Gross margin97.82%—
Operating margin38.98%—
Net margin30.16%—
52-week high$11.22$53.65
52-week low$6.23$21.95
Distance from 52-week high-35.65%-41.53%
Analyst consensusbuystrong_buy
Avg. price target upside+183.24%+99.11%
Average volume4.97M737.14K
Shares outstanding257.30M54.68M
Employees435141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BCRX has outperformed MAZE by 17.1 percentage points over the past year.

About BioCryst Pharmaceuticals

BCRX stock →

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees

About Maze Therapeutics

MAZE stock →

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

BCRX vs MAZE FAQ

Which is bigger, BioCryst Pharmaceuticals or Maze Therapeutics?

BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $1.86B compared with $1.72B for Maze Therapeutics (MAZE).

Which stock has performed better over the past year, BCRX or MAZE?

BCRX returned +3.59% over the past 12 months, compared with -13.49% for MAZE (price return, excluding dividends). Past performance does not predict future results.

Are BioCryst Pharmaceuticals and Maze Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons